
Resources
We play an active role in breaking down and analyzing current events in the healthcare industry for our members, policy influencers and the Canadian public.
Our team produces media releases, reports, policy papers and other informative content to keep you up to date on the most pressing issues facing our industry. Here in our resources section, you’ll find our most recent work.
ANALYSIS & REPORTS

The Canadian Research and Development Pharmaceutical Sector, 2021
This study examines the contribution of the Canadian research and development (R&D) pharmaceutical sector on the Canadian economy in 2021. […]
RESEARCH

Bluesky Project
Reimagining Canada’s Approval and Reimbursement System for Innovative Medicines February 2022

2022 Code of Ethical Practices
Our Code of Ethical Practices guides the activities of all our members’ employees as they interact with stakeholders to commercialize prescription medicines (excluding medical devices and over-the-counter products). Adherence to the Code is a condition of membership.
INFOGRAPHICS & DATA

Two years is too long – Understanding Canada’s Drug Access Pathway
Canadians wait two years for access to new medicines through our public drug plans. That’s a full year longer than patients in most other peer countries. Two years can feel like a lifetime for a patient waiting for access to life-saving medicines or treatments.

Better Access Better Health
More than 23-million Canadians depend on access to medicines and vaccines through employer-sponsored private plans.
Browse by topic

Canadian Public Reimbursement Timelines
One of Innovative Medicines Canada’s guiding principles is to offer solutions to challenges in the Canadian health system. Access to new medicines is one such challenge.

Pharma 101
Use this beginner’s guide to understand the basics of how our industry works.

Advocacy
Everything you need to make an informed decision about our industry.

Newsroom
Breaking down and analyzing current events in the healthcare industry for our members, policy influencers and the Canadian public.